Biomarin Pharmaceutical Inc logo

Biomarin Pharmaceutical Inc - BRDR

BSP:B1MR34 (USA)   BRDR
R$ 235.55 (+7.07%) Apr 12
104.83
P/B:
3.51
Market Cap:
R$ 89.40B ($ 17.47B)
Enterprise V:
R$ 89.52B ($ 17.49B)
Volume:
1.00
Avg Vol (2M):
23.00
Also Trade In:
Volume:
1.00
Avg Vol (2M):
23.00

Business Description

Biomarin Pharmaceutical Inc logo
Biomarin Pharmaceutical Inc
NAICS : 325412 SIC : 2834
ISIN : BRB1MRBDR001

Share Class Description:

BSP:B1MR34: BRDR
Description
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.
Name Current Vs Industry Vs History
Cash-To-Debt 0.98
Equity-to-Asset 0.72
Debt-to-Equity 0.22
Debt-to-EBITDA 3.54
Interest Coverage 9.44
Piotroski F-Score 6/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 6.2
Distress
Grey
Safe
Beneish M-Score -2.14
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 99.75
9-Day RSI 96.4
14-Day RSI 89.12
6-1 Month Momentum % -4.29
12-1 Month Momentum % -13.27

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 2.51
Quick Ratio 1.57
Cash Ratio 0.91
Days Inventory 698.71
Days Sales Outstanding 86.77
Days Payable 197.2

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -1.2
Shareholder Yield % -0.01

Financials (Next Earnings Date:2024-04-24)

BSP:B1MR34's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Biomarin Pharmaceutical Inc Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil R$) 12,033.068
EPS (TTM) (R$) 2.195
Beta -0.42
Volatility % 24.18
14-Day RSI 89.12
14-Day ATR (R$) 1.512555
20-Day SMA (R$) 217.8975
12-1 Month Momentum % -13.27
52-Week Range (R$) 195.19 - 245.42
Shares Outstanding (Mil) 379.55

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 6
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Biomarin Pharmaceutical Inc Filings

Filing Date Document Date Form
No Filing Data

Biomarin Pharmaceutical Inc Stock Events

Financials Calendars
Event Date Price(R$)
No Event Data

Biomarin Pharmaceutical Inc Frequently Asked Questions

What is Biomarin Pharmaceutical Inc(BSP:B1MR34)'s stock price today?
The current price of BSP:B1MR34 is R$235.55. The 52 week high of BSP:B1MR34 is R$245.42 and 52 week low is R$195.19.
When is next earnings date of Biomarin Pharmaceutical Inc(BSP:B1MR34)?
The next earnings date of Biomarin Pharmaceutical Inc(BSP:B1MR34) is 2024-04-24.
Does Biomarin Pharmaceutical Inc(BSP:B1MR34) pay dividends? If so, how much?
Biomarin Pharmaceutical Inc(BSP:B1MR34) does not pay dividend.

Press Release

Subject Date
No Press Release